Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)

Next Previous
Trial Profile

A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sugammadex (Primary) ; Rocuronium bromide; Suxamethonium chloride
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Acronyms CRoSSECT

Most Recent Events

  • 26 Oct 2022 Primary endpoint has been met, (Recovery time of T1 to 90% baseline); as per Results presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
  • 26 Oct 2022 Status has been changed to completed, as per Results presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
  • 26 Oct 2022 Results presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top